Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEVOsq: Pembrolizumab + Vorinostat in Squamous Cell Carcinoma
NCT04357873Phase 2Completed
- Sponsor
- Unicancer
- Start
- Oct 2020
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, vorinostat in head and neck squamous cell carcinoma (HNSCC), squamous cell carcinoma of the lung (LSCC), Cervical Cancer (CC), anal cancer, vulvar cancer, sponsored by Unicancer. Started Oct 2020; status: completed.
02
Drugs
pembrolizumabvorinostat
03
Conditions
head and neck squamous cell carcinoma (HNSCC)squamous cell carcinoma of the lung (LSCC)Cervical Cancer (CC)anal cancervulvar cancer
Beyond the preview
Go deeper on NCT04357873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04357873.